Researchers established a point of departure for CBD hepatotoxicity using human HepaRG liver cell spheroids, providing data to inform safe dosing guidelines.
Toxicologists, regulatory scientists, CBD product manufacturers, and pharmacologists.
Safety threshold definedHepaRG liver spheroids identified CBD concentrations where hepatotoxic effects begin
What the researchers found
Using human HepaRG liver cell spheroids, researchers identified concentration thresholds at which CBD begins to cause liver cell damage, providing a quantitative basis for establishing safe exposure limits.
Why it matters
With CBD products widely available and often unregulated, establishing evidence-based safety thresholds for liver toxicity is crucial for consumer protection and regulatory guidance.
The numbers in context
The study used HepaRG spheroids (3D human liver cell models) to determine CBD concentrations that trigger hepatotoxic responses, with reference to clinical observations of ALT elevations in Epidiolex trials.
How the study worked
In vitro toxicology study using human HepaRG liver cell spheroids to establish concentration-response relationships for CBD hepatotoxicity.
Who was studied
Human HepaRG liver cell spheroids (in vitro model).
What this study cannot tell us
In vitro models may not fully replicate in vivo liver metabolism and clearance; spheroid cultures lack full hepatic architecture; individual genetic variation affects real-world toxicity.
How to read the evidence
In vitro toxicology with human-relevant cell model; provides mechanistic data but requires in vivo validation.
When this study was published
Recent study using advanced 3D cell culture technology.
The bigger picture
This type of quantitative safety assessment bridges the gap between clinical observations of CBD-related liver issues and the need for evidence-based maximum safe exposure levels for the broad consumer market.
Replication
Complements clinical observations and computational modeling (like RTHC-04699) of CBD hepatotoxicity.
Funding
Not specified
Conflicts of interest
Not specified
Questions still open
- How does the in vitro threshold compare to clinical CBD doses?
- Do other cannabinoids affect the hepatotoxicity threshold?
- Should consumer CBD products have dosing limits based on liver safety?
Read the original research
Establishment of a point of departure for CBD hepatotoxicity employing human HepaRG spheroids.
Toxicology, 488, 153469
Citation
Li, Jinpeng; Zagorski, Joseph W; Kaminski, Norbert E. (2023). Establishment of a point of departure for CBD hepatotoxicity employing human HepaRG spheroids.. Toxicology, 488, 153469. https://doi.org/10.1016/j.tox.2023.153469